Last reviewed · How we verify
NCT04325672
Convalescent Plasma to Limit Coronavirus Associated Complications
Withdrawn
Phase 2
Last updated 8 April 2020
What this trial tests
Phase 2 trial testing Convalescent Plasma in Coronavirus. Withdrawn.
Timeline
1 April 2020
Primary endpoint
31 December 2022
31 December 2022
31 December 2022
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Start date | 1 April 2020 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
Drugs / interventions tested
- Convalescent Plasma — full drug profile →
Conditions studied
- Coronavirus — all drugs for Coronavirus →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Coronavirus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044 -
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Chai KL, Valk SJ, Doree C, et al · · 2020 · cited 148× · PMID 32648959 · DOI 10.1002/14651858.cd013600.pub2 -
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ, Piechotta V, Chai KL, Doree C, et al · · 2020 · cited 126× · PMID 32406927 · DOI 10.1002/14651858.cd013600 -
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4 -
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.
Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, et al · · 2020 · cited 91× · PMID 32562483 · DOI 10.1016/j.xcrm.2020.100016 -
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S, Ahmed N, Ahmed N, Ratts R, et al · · 2020 · cited 69× · PMID 33059711 · DOI 10.1186/s12985-020-01415-w -
The current understanding and potential therapeutic options to combat COVID-19.
Pooladanda V, Thatikonda S, Godugu C. · · 2020 · cited 56× · PMID 32437797 · DOI 10.1016/j.lfs.2020.117765 -
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, et al · · 2020 · cited 29× · PMID 32623296 · DOI 10.1016/j.ctrv.2020.102063
Verify or expand the search:
- PubMed search for NCT04325672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Convalescent Plasma
Trials testing the same drug.
- NCT04884477 — COVID-19 Infection in Patients Receiving Anti-CD20 Therapy · completed
- NCT04539275 — VA CoronavirUs Research and Efficacy Studies-1 · Phase 3 · terminated
- NCT04456413 — Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection · Phase 2 · terminated
- NCT04558476 — Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation · Phase 2 · completed
- NCT04513158 — Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection · Phase 2 · terminated
Other recruiting trials for Coronavirus
Currently open trials in the same condition.
- NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
- NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
- NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
- NCT04568148 — COVID-19 Biorepository · active not recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04325672 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 8 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04325672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing